Transition report pursuant to Rule 13a-10 or 15d-10

Stockholders' Equity (Details Textual)

v3.21.1
Stockholders' Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 6 Months Ended 12 Months Ended
Oct. 30, 2020
Dec. 31, 2020
Jun. 30, 2020
Sep. 01, 2020
Jan. 15, 2020
Jun. 30, 2019
Jun. 17, 2019
Common stock, shares authorized   75,000,000 75,000,000     10,589,746  
Common stock, par value   $ 0.0001 $ 0.0001     $ 0.0001  
Preferred stock, shares authorized   5,000,000 5,000,000     5,000,000  
Preferred stock, par value   $ 0.0001 $ 0.0001     $ 0.0001  
Sale of stock, description   we sold 5,750,000 units at a purchase price of $10.00 per unit, inclusive of 750,000 units sold to the underwriters on February 8, 2018, upon the underwriters’ election to fully exercise their over-allotment option.          
Issue of Class A common stock   2,667,349   4,798,271      
Proceeds from mergers   $ 18.0          
Merger related expense   $ 4.4          
Exercise price   $ 11.50         $ 10.16
Convertible into shares of common stock per share         $ 9.00    
IPO [Member]              
Gross proceeds $ 12.0            
Convertible into shares of common stock per share $ 2.40            
Proceeds from offering cost $ 1.0            
Proceeds from net $ 11.0            
Sale of stock 5,000,000            
Private Placement [Member]              
Sale of stock, description     The Company also provided each investor the ability to purchase additional shares of Akerna common stock at a price of $10.21 per share, up to their pro rata share of the 901,074 Private Placement Shares purchased.        
Issue of Class A common stock   901,074          
Aggregate purchase price   $ 9.2